Skip to content
Aussie8 – Lifestyle
Author:
NeOnc Technologies Holdings, Inc.
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
August 10, 2026
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
August 10, 2026
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
July 27, 2026
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
July 15, 2026
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
June 23, 2026
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
June 16, 2026
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
May 18, 2026
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
May 5, 2026
NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results
April 14, 2026
NeOnc Provides Business Update and Reports Q4 2025 Financial Results
April 1, 2026
1
2
Next Page
→